Brief: Alector Announces Completion Of Enrollment In The Progress-Ad Phase 2 Clinical Trial Of Al101/Gsk4527226 In Individuals With Early Alzheimer’S Disease
17/04/2025 14:06
April 17 (Reuters) - Alector Inc ALEC.O: ALECTOR ANNOUNCES COMPLETION OF ENROLLMENT IN THE PROGRESS-AD PHASE 2 CLINICAL TRIAL OF AL101/GSK4527226 IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE Source text: ID:nGNX5ZCWfJ Further company coverage: ALEC.O ((Reuters.Briefs@thomsonreuters.com;))